Skip to NavigationSkip to content

MedImmune Ventures appoints Ron Laufer

Published on: 18/06/10

Ron Laufer has joined MedImmune's venture capital arm as senior managing director.

The company, which is the worldwide biologics unit for AstraZeneca, said Laufer wold strengthen its long-term commitment to supporting scientific innovation through strategic venture capital investments.

"I am delighted to join MedImmune Ventures at this exciting time in biopharmaceutical research," said Laufer. "I look forward to building on a successful history and supporting promising products and companies as they pursue our shared commitment to improving patient health."

Laufer has more than 15 years industry experience, during which he co-founded Lilly Ventures, Eli Lilly and Company's corporate venture capital fund.

He was also a managing director for healthcare-focused investment firm Visium Asset Management.

Mission Statement
InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma jobs, pharma events, and pharma service company listings.
Site content is produced by our editorial team for InPharm.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
a site by SiftGroups